A Joe Mikhael Icebreaker Fulfilled
Dr. Gotlib talks about fulfilling a lifelong dream of spending time with sloths by visiting Kids Saving the RainForest while on a recent trip to Costa Rica.
Another Therapeutic Agent in the Pipeline for Preventing Acute Vaso-Occlusive Events in Sickle Cell Disease
Dr. DeBaun looks at experiments using ARQ 092 as a possible therapeutic agent for preventing acute vaso-occlusive events in sickle cell disease.
Insightful critiques and informed commentary of important ongoing clinical trials
Dr. Linkins covers a study that compares apixaban with no anticoagulants for prevention of a composite of fatal and nonfatal venous thromboembolism in children with a central venous catheter and newly diagnosed ALL, lymphoma or mixed-phenotype acute leukemia.
Drs. Raetz and Kovacsovics cover a trial meant to develop a precision medicine approach for the treatment of AML.
Dr. Moss covers a study that compares the PD-1 inhibitor pembrolizumab with brentuximab vedotin in subjects with relapsed or refractory classical HL.
Dr. Garcia discusses a study that tests a new therapeutic approach with antifibrinolytic agents to chemotherapy-associated thrombocytopenia.
Dr. Abdel-Wahab and Dr. Taylor cover a study that measures the safety of combination ABT-199 and hypomethylating agents in older adults with acute myelogenous leukemia (AML), who are treatment-naive and not eligible for standard induction therapy.
Dr. Cuker and Dr. George discuss a study that evaluates the safety, tolerability, and pharmacokinetics of SPK-9001 in subjects with hemophilia B.
Dr. Keel talks about a study that compares risks and benefits of alloHCT in older patients with higher-risk myelodysplastic syndromes.
Dr. Raje and Dr. Yee discuss a study that looks at the use of pembrolizumab in combination with lenalidomide or pomalidomide to treat multiple myeloma as a form of checkpoint inhibition, a new important tool in cancer treatment.
Dr. Stimpson and Dr. DeBaun look at a trial that evaluates research for HCT in severe sickle cell disease using HLA-identical siblings and unrelated donors for HCT compared with standard care due to the absence of a suitable donor.
Dr. Raetz and Dr. Loh cover a new study in pediatric ALL that tests the contribution of ruxolitinib to traditional chemotherapy for newly diagnosed, genetically defined subsets of patients who are known to have poor outcomes with standard therapy.
May-June 2017Volume 14, Issue 3
A new Compendium providing updated clinical information to "Ask the Hematologist" articles published in The Hematologist from 2010 to 2015 is now available.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology